The present invention relates to amorphous aleglitazar, preferably together with a surface stabiliser in the form of a stable composition. The invention further relates to methods of preparing stable amorphous aleglitazar, and dosage forms containing stable amorphous aleglitazar. Finally, the invention relates to the use of a dosage form comprising an amorphous PPAR modulator for the treatment of diabetes.
展开▼
